Atrial fibrillation (AF) accounts for most embolic strokes, especially in elderly individuals. Although anticoagulation is known to reduce the risk of embolic stroke, a significant proportion of patients have relative or absolute contraindications to anticoagulation. The left atrial appendage has been implicated as the major source of emboli in more than 90% of ischemic strokes in nonvalvular AF. Left atrial appendage occlusion offers an alternative for stroke prevention in patients with an elevated stroke risk (CHADS 2 score !2 or CHA 2 DS 2 -VASc score !3) who have a rationale for avoiding long-term oral anticoagulation after a shared decision-making process. However, there remain significant challenges in left atrial appendage occlusion therapy related to patient selection, the procedure itself, and postprocedural patient management decisions. In this review article, we discuss some of these challenges in a case discussionebased approach.
A trial fibrillation (AF) accounts for most embolic strokes, especially in elderly individuals. It has major societal implications for our aging population, affecting approximately 7 million individuals in the United States. 1 Although systemic anticoagulation is known to reduce the risk of embolic stroke, a significant proportion of patients have relative or absolute contraindications to anticoagulation. Many patients who are "ideal candidates for blood thinners" do not receive anticoagulation or end up discontinuing it over the course of therapy. [2] [3] [4] In a large study involving patients with new-onset AF (n¼45,092) from HealthCore Integrated Research Database from 2010 through 2013, 72.7% of the patients discontinued their oral anticoagulation, with nearly one-fourth discontinuing treatment within 3 months. 5 Likewise, only 47.5% of the novel oral anticoagulant (NOAC)etreated patients with AF in a large US commercial insurance database (n¼64,661) were noted to have high adherence at 1 year. 6 The left atrial appendage (LAA) has been implicated as the major source of emboli in more than 90% of ischemic strokes. Local siteespecific therapy using the Watchman LAA closure device (Boston Scientific) was thus developed, tested in randomized controlled trials, and finally approved for the prevention of stroke in the setting of nonvalvular AF. Based on the results of pivotal trials, Food and Drug Administration (FDA) approval was granted in March 2015 for patients with nonvalvular AF at increased risk for stroke who had an appropriate reason to seek an alternative to long-term anticoagulation. 7 The Centers for Medicare & Medicaid Services, for reimbursement purposes, subsequently approved the Watchman device as an alternative for stroke prevention in patients with an elevated stroke risk (CHADS 2 score !2 or CHA 2 DS 2 -VASc score !3) who could be treated with short-term warfarin but in whom there is a rationale for avoiding longterm oral anticoagulation based on a shared decision-making process. 8 Such indications although helpful, do not take into account the nuances of clinical care for specific patients. The following clinical scenarios have been selected to illustrate some of the practical issues faced in the care of these patients and to address potential approaches to possible resolution. All the described cases fall under 1 of the following 4 categories: (1) preimplant patient selection criteria, (2) specific devices considered, (3) procedural performance, and (4) postimplant issues. All the patients were evaluated and the LAAO procedures were performed from January 1, 2016, through April 30, 2017, after informed consent was obtained and after a shared decision-making process had been completed.
CURRENTLY AVAILABLE STRATEGIES FOR LAAO
As the only LAAO device with randomized trial data supporting its use, the Watchman is the only FDA-approved option for LAAO. In the pivotal Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation (PROTECT AF) trial, patients with nonvalvular AF (n¼707) and an additional risk factor for stroke (mean CHADS 2 score of 2.2) were randomized 2:1 to receive doseadjusted warfarin or LAAO with the Watchman device. 9 There was no significant difference in the primary end point of stroke, systemic embolism, and cardiovascular or unexplained death between the 2 arms (3 vs 4.9 per 100 patientyears in the Watchman group vs the warfarin group [relative risk, 0.62; 95% CI, 0.35-1.25]). However, the rate of primary safety events was higher in the Watchman arm (relative risk, 1.69; 95% CI, 1.01-3.19), including pericardial effusion (5% of the Watchman patients), major bleeding (3.8%), and device embolization (0.6%). 9 A follow-up trial, Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long-term Warfarin Therapy (PREVAIL), was then performed due to safety concerns raised by the FDA after the results of the PROTECT-AF trial. 10 A total of 407 patients (with a relatively higher CHADS 2 score of 2.6 compared with PROTECT-AF) were randomized in a 2:1 manner to receive the Watchman device and warfarin. The Watchman device was demonstrated to be noninferior to warfarin in terms of the co-primary efficacy end point of stroke or systemic embolism more than 7 days after randomization. 10 Procedural complications decreased to 4.2% compared with 8.7% in the PROTECT AF trial (P¼.004). 10 Another option for endocardial LAAO is an Amplatzer cardiac plug (ACP) Amulet device (Abbott) made of nitinol mesh. The device has a distal anchoring lobe that is positioned in the LAA body and is connected by a waist to a proximal disc that seals the LAA orifice. The largest registry data for the ACP included 1047 patients and reported a 2.3% annual stroke rate in patients with the ACP device, a 59% reduction compared with the predicted rate based on the cohort's mean CHA 2 DS 2 -VASc score. 11 An investigational device exemption trial is evaluating the safety and efficacy of the ACP Amulet device with the objective of demonstrating its noninferiority to the Watchman device.
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LARIAT (SentreHEART) is a percutaneously delivered ligature that is placed around the LAA neck using transseptal endocardial and pericardial access. No postprocedural anticoagulation is required after Lariat. Lariat and other epicardial approaches for LAAO, such as the newer AEGIS (Aegis Medical), are, thus, valuable in patients with absolute contraindications to anticoagulation or unsuitable LAA anatomy for endocardial occlusion. Lakkireddy et al 13 presented the largest available data on Lariat from a multicenter registry of 712 patients, reporting procedural success in 95.5%, with low procedural mortality (0.14%). However, there have been some procedural safety concerns regarding LAA perforation and cardiac tamponade, and it is not FDA approved for this indication currently. Such patients with contraindications
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to anticoagulation might also be candidates for open and minimally invasive thoracoscopic surgical LAAO techniques, especially when undergoing cardiac or thoracoscopic AF surgery.
14 Although the data on surgical techniques has been limited, with concerns for incomplete closure, newer devices, such as the AtriClip system (AtriCure Inc), likely offer superior occlusion results. 15 The recently published results from the first-in-man study of the AtriClip device (n¼291) demonstrated successful LAA exclusion in all the patients, with no devicerelated complications throughout follow-up (mean AE SD of 36AE23 months). 16 
PREIMPLANT PATIENT SELECTION
Patient A A 76-year-old woman with a history of amyloidosis and nonvalvular AF and a CHA 2 DS 2 -VASc score of 7 being treated with warfarin was found to have an ischemic stroke with hemorrhagic transformation involving the left occipital parietal area with multiple other subacute infarcts. In addition, magnetic resonance imaging showed scattered areas of microhemorrhage consistent with cerebral amyloid angiopathy. The patient was transitioned from warfarin to apixaban therapy after this b Endocardial LAAO has not be tested in randomized trials for this indication, and epicardial LAAO (Lariat) is not Food and Drug Administration approved. AF ¼ atrial fibrillation; CABG ¼ coronary artery bypass graft; LAA ¼ left atrial appendage.
episode and was referred for consideration of LAAO.
Patient B
An 84-year-old woman with a history of coronary artery disease, paroxysmal AF, a CHA 2 DS 2 -VASc score of 4, and a HAS-BLED score of 4 was referred after an episode of subdural hematoma while taking warfarin after a fall. After discussion with the patient's family, she was believed to be at high fall risk given her frailty and balance issues. She was otherwise independent in her activities of daily living. Figure 1 shows an algorithm for guiding appropriate patients for LAAO. The Table outlines some of the challenges encountered during evaluation of such patients and their possible solutions. Both the PROTECT AF and PREVAIL trials included patients without absolute contraindications for warfarin. Thus, the most scientifically validated indication for LAAO based on the published data is in patients who are at an increased risk for bleeding but can tolerate short-term anticoagulation. These patients are usually those with previous nonelife-threatening bleeding events or those at increased risk for future bleeding (high HAS-BLED scores [typically !3], history of coronary artery disease while receiving dual antiplatelet therapy, and patients with endstage renal disease [creatinine clearance <15-30 mL/min/1.73 m 2 ] [to convert to mL/s/m 2 , multiply by 0.0167]) or elderly patients with a high fall risk. However, the decision to proceed with LAAO in any patient should be made using a shared decision-making process similar to any other interventional procedure. The upfront risks involved with an invasive procedure, the benefits of reduced bleeding in the future, as well as the noninferiority of LAAO to warfarin in terms of study end points should be explained to the patients. A recent patient-level meta-analysis of the PROTECT AF trial, the PREVAIL trial, and their continued-access registry data has further concluded that the Watchman device is superior compared with warfarin in terms of lower hemorrhagic stroke (0.15 vs 0.96 events per 100 patient-years of follow-up), cardiovascular/unexplained death (1.1 vs 2.3 events per 100 patient-years; P¼.006), and nonprocedural bleeding (6 vs 11.3 events per 100 patient-years; hazard ratio, 0.51; P¼.006).
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The initial safety concerns notwithstanding, the safety of LAAO in "real-world" clinical practice has been demonstrated, with low rates of cardiac tamponade (1.09%), procedural stroke (0.078%), and mortality (0.078%) reported from 3822 consecutive Watchman cases after FDA approval. 18 The NOACs are currently the first-line therapy for anticoagulation in patients with AF. Previous studies have demonstrated that NOACs have better safety and efficacy profiles compared with warfarin. 19 However, the attendant bleeding risks and medication adherence remain issues even with NOACs. 6 Discontinuation of NOACs is accompanied by an increased risk of stroke in patients with a CHA 2 DS 2 -VASc score of 2 or greater. 6 There are no substantial comparative data between LAAO therapies and NOACs in patients with AF, including patient A, who was started on a NOAC after his bleeding episode. In a recent systematic review and meta-analysis of randomized studies, the authors found that although NOACs were superior to warfarin in terms of stroke/systemic embolism, there was no significant difference between the Watchman and warfarin arms. Although there was again no direct comparison available between the Watchman and NOACs, the overall stroke/systemic embolism rates in the pooled trial populations were comparable (3.4% for Watchman vs 3.5% for NOACs). 20 Future randomized trials are under way comparing LAAO with NOACs in the absence of any such direct head-to-head comparison. 21 Patient A had a history of intracranial bleeds in the setting of cerebral amyloid angiopathy, which increased her future risk of intracranial bleeds. A consultation with neurology led to the conclusion that short-term anticoagulation might be feasible if LAAO was being considered. Patient B had a subdural hematoma after a fall and was believed to be at high future fall risk, increasing her chances of future bleeding. We had a discussion with both our patients regarding their future risk of stroke, bleeding, comparative data on NOACs, as well as the safety and efficacy data on LAAO. Both patients chose LAAO and have done well with 6 months of follow-up.
Patient C
A 69-year-old woman presented with a history of severe symptomatic aortic valve stenosis and paroxysmal AF. She had been treated with NOACs but they were discontinued because of repeated overt gastrointestinal bleeding as well as mucosal bleeds involving the gums and nose. The patient was initially evaluated for aortic stenosis and underwent successful transcatheter aortic valve replacement. The patient was scheduled to undergo LAAO using the Watchman device during the time she was receiving anticoagulation after transcatheter aortic valve replacement. However, she developed anemia with a hemoglobin level of 7.6 g/dL (to convert to g/L, multiply by 10) before the procedure while receiving anticoagulation.
Patient D
An 82-year-old man with paroxysmal AF and a CHA 2 DS 2 -VASc score of 4 had a history of amyloid angitis associated with multiple brain bleeds and seizures and was not receiving any anticoagulation. After neurologic consultations, even short-term anticoagulation was contraindicated in this patient due to advanced cerebral amyloid angiopathy. The patient was referred for evaluation for various options for LAAO.
Patients C and D were intolerant to even short-term anticoagulation and possibly represent the most common reason for patient referral for LAAO. In a recent survey involving 24 centers in Europe, LAAO was most commonly (94%) performed in patients with absolute contraindication to anticoagulation, 22 including patients with a history of major lifethreatening or intracranial bleeding. As mentioned previously herein, this specific patient population has not been included in any large randomized trials. The earliest data on this specific cohort of patients came from the Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO) feasibility study, which studied the first endocardial LAAO device in 64 patients with contraindications to anticoagulation. The patients were given only antiplatelet therapy after LAAO, and during follow-up of 129 documented patient-years, there was a lower-than-predicted rate of stroke based on CHADS 2 score (3.8% vs 6.6% predicted). This concept of only antiplatelet agents after LAAO has also been applied using the ACP. In a study with 52 patients, LAAO with ACP followed by dual antiplatelet therapy for 1 to 3 months and single antiplatelet agent thereafter, there were low rates of embolic and bleeding events at 20 months. 23 The most recent data on patients with AF with absolute contraindications to anticoagulation and LAAO comes from the ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology (ASAP). 24 The authors followed 150 patients with nonvalvular AF who underwent LAAO with the Watchman device (mean AE SD CHA 2 DS 2 -VASc score of 4.4AE1.7) for a mean AE SD duration of 14.4AE8.6 months. The annual ischemic stroke rate of 1.7% reported in the study represented a 64% reduction from the historically expected stroke rate in a similar patient population treated with antiplatelet agents alone. A randomized trial (Assessment of the WATCHMAN Device in Patients Unsuitable for Oral Anticoagulation [ASAP TOO]), which is specifically evaluating this patient population by randomizing them to receive either Watchman þ ASA/Plavix or dual antiplatelet therapy alone, is in progress.
Patient C was initially stabilized from a hematologic standpoint. A gastroenterologist evaluated the patient, who was found to have primarily small-bowel arteriovenous malformations, which were managed conservatively, and anticoagulation was stopped. The patient eventually underwent LAAO with postprocedural antiplatelet therapy alone after discussion regarding the evidence for this strategy as noted previously herein. Patient D, after discussion regarding the various treatment strategies and realizing that he could not be started on any anticoagulation even for the short-term, chose the Lariat procedure for LAAO.
Patient E
An 82-year-old man had a history of chronic AF, a CHA 2 DS 2 -VASc score of 7, and a history of embolic stroke in his anterior circulation while taking warfarin. The patient was switched to a NOAC and had multiple nosebleeds requiring intervention. The patient also had a history of coronary artery bypass grafting and bioprosthetic mitral valve replacement for severe mitral valve regurgitation due to a torn chord several years ago, with a normally functioning valve on most recent echocardiogram.
Patients with valvular AF (especially rheumatic mitral valve disease) are not ideal candidates for LAAO because the body of the left atrium is itself a major source of thrombus in this patient population. However, substantial disagreement exists on the differentiation between valvular and nonvalvular AF. 25 The different NOAC trials had varying exclusion criteria for patients with valvular heart disease. Although all patients with prosthetic heart valves and hemodynamically relevant valvular disorders were excluded from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, 26 only patients with moderate or severe mitral stenosis were excluded from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 27 The Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial excluded patients with hemodynamically significant mitral stenosis or prosthetic heart valves (annuloplasty with or without a ring, commissurotomy, and valvuloplasty were permitted). 28 The 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines for AF management define nonvalvular AF as occurring in the absence of rheumatic heart disease and prosthetic mitral (mechanical and bioprosthetic) valves or mitral valve repair.
14 Although patient E was considered an appropriate candidate for LAAO given his bleeding risk, the referring physician was concerned that this was valvular AF. An extensive review of patient E's history revealed that he had a long-standing history of AF before mitral valve replacement, which was done for severe symptomatic mitral regurgitation due to a flail leaflet. Mitral regurgitation of nonrheumatic etiology in the presence of AF does not result in low flow state in the left atrium and has not been associated with increased risk of thromboembolic events. 29 Thus, patient E was referred for LAAO in the presence of a heightened embolic risk and bleeding complications even while taking NOACs. A 65-year-old man with a CHA 2 DS 2 -VASc score of 3 was referred for LAAO therapy after he was noted to have LAA thrombi despite anticoagulation. The patient continued to have persistent spontaneous echocardiographic contrast in the LAA even after increasing international normalized ratio goals. On preprocedural computed tomography, the diameter of the LAA ostium was noted to be 40 mm.
Patient G
A 68-year-old man with history of AF (CHA 2 DS 2 -VASc score of 3 and HAS-BLED score of 3) and adenocarcinoma of the esophageal gastric junction was referred for LAAO given his history of gastrointestinal malignancy and associated bleeding potential. The patient's preprocedural evaluation, including computed tomography, was completed, and he was believed to be a suitable candidate for LAAO using a Watchman device. Transesophageal echocardiography (TEE) could not be performed preprocedurally or intraprocedurally given the patient's history of esophagectomy with gastric pull through for adenocarcinoma.
The Watchman device, available in 5 sizes from 21 to 33 mm, has a nitinol frame with 10 active fixation barbs covered with a 160-mm polyethylene terephthalate membrane to prevent embolization. The maximal LAA ostium size needs to be 17 to 31 mm, and the workable LAA depth should be greater than the ostium maximal width. Patient F had an LAA ostium that was wider than recommendations ( Figure 2 ) and instead underwent successful surgical AtriClip, described earlier. Another option for such patients with a smaller LAA is the ACP Amulet device described earlier. Amulet is available in 8 different sizes from 16 to 34 mm and can accommodate smaller LAA anatomies (maximum landing zone width of 11-31 mm).
The Watchman procedure is performed under TEE guidance to confirm the absence of LAA thrombus, determine the size of the LAA, guide transseptal puncture, and confirm adequate positioning and compression of the device without a significant leak around it. However, some patients, such as patient G (with esophagectomy), have anatomical reasons that preclude TEE. Therefore, we performed the procedure successfully under intracardiac echocardiography (ICE) guidance (Figure 3) . Also, ICE offers the advantage of avoiding general anesthesia and intubation. The disadvantages of using ICE include limited 45 views for LAA evaluation, which can sometimes be partly overcome by imaging the LAA from the right ventricular outflow tract or advancing the ICE probe through the transseptal puncture site into the LA. [30] [31] [32] In a series of 27 patients, Matsuo et al 32 reported successful ICE-guided LAAO using the Watchman device in all the patients. We selected ICE for our patient as well and were able to successfully deploy the Watchman device without any complications.
CONCLUSION
Left atrial appendage occlusion is a valuable alternative for reducing the risk of thromboembolic stroke in patients with AF who have contraindications or intolerance to oral anticoagulants. However, clinicians should be aware of appropriate patient selection, preprocedural planning, and intraprocedural challenges for ensuring the best patient and procedural outcomes. Future studies and innovations will be important in dealing with certain challenges, such as difficult LAA anatomies. 
